Can Cardiac MRI Replace Invasive Heart Transplant Biopsies?

Monitoring acute cellular rejection after heart transplantation is crucial for long-term patient survival. Historically, clinicians used endomyocardial biopsy as the gold standard tool for surveillance. However, this invasive procedure carries significant risks like bleeding and cardiac perforation. Fortunately, researchers are evaluating a cardiac MRI transplant rejection strategy to noninvasively monitor these high-risk patients.

Why cardiac MRI transplant rejection monitoring matters

Recently, a prospective study evaluated 17 adult heart transplant recipients using multiparametric magnetic resonance imaging. Specifically, researchers performed serial cardiac MRI scans with T1- and T2-mapping alongside routine biopsies. Consequently, they compared relaxation times based on histopathological evidence of acute cellular rejection. The results showed that transplant recipients had significantly higher T1 and T2 values than healthy controls. Moreover, global T2-mapping successfully identified rejection episodes with high specificity. Therefore, this noninvasive tool could safely reduce the frequency of invasive biopsies.

The Role of T2-Mapping Versus T1-Mapping

Notably, cardiac biomarkers like troponin failed to differentiate between patients with and without rejection. In contrast, T2-mapping proved highly effective for detecting acute inflammatory changes. Specifically, a global T2-mapping cutoff of 51 ms yielded an impressive 92% specificity. However, T2-mapping exhibited a modest sensitivity of only 46%. Meanwhile, T1-mapping showed elevated values only in selected myocardial segments. Because of this inconsistent inferoseptal pattern, global T1-mapping had limited utility for rejection screening. Thus, clinical protocols should prioritize T2-mapping for noninvasive graft monitoring.

Frequently Asked Questions

Q1: Why do clinicians prefer T2-mapping over T1-mapping for detecting transplant rejection?

Specifically, T2-mapping excels because it directly highlights myocardial edema, which indicates acute rejection. In contrast, T1-mapping values show inconsistent regional patterns, limiting their diagnostic reliability across the entire myocardium.

Q2: Can cardiac biomarkers replace endomyocardial biopsies for surveillance?

Unfortunately, standard cardiac biomarkers like NT-proBNP and troponin do not reliably identify acute cellular rejection episodes. Therefore, clinicians must rely on advanced imaging techniques or invasive biopsies instead.

References

1. Sokolska JM et al. Multiparametric cardiac MRI in the diagnosis of transplant rejection in patients after orthotopic heart transplantation. Eur Radiol. 2026 May 26. doi: 10.1007/s00330-026-12631-3. PMID: 42189216.
2. Vermes E et al. Cardiovascular magnetic resonance in heart transplant patients: diagnostic value of quantitative tissue markers: T2 mapping and extracellular volume fraction, for acute rejection diagnosis. J Cardiovasc Magn Reson. 2018;20:59.
3. Giri S et al. Cardiac magnetic resonance T2 mapping in the monitoring and follow-up of acute cardiac transplant rejection: a pilot study. Circ Cardiovasc Imaging. 2012;5(6):766-772.